Trial Profile
A Phase I Study of the Safety and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs IMNN 001 (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms OVATION I
- Sponsors Celsion Corporation; Imunon
- 19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
- 14 Apr 2022 Results published in the Celsion Corporation Media Release.
- 14 Apr 2022 According to a Celsion Corporation media release, data from the Synthetic Control Arm was presented at the Annual Meeting of the American Association for Cancer Research (AACR).